The 2000 International AIDS Conference in Durban, South Africa,focused the world's attention on disparities between rich andpoor countries with respect to access to antiretroviral drugs.At that time, an estimated 7000 people in Africa had accessto effective combination antiretroviral regimens. Though thenumber exceeds 100,000 today, it is still a far cry from the8 million who are thought to require such therapy. In response,in 2003, the World Health Organization (WHO) launched an ambitiousprogram termed "3 by 5" in an attempt to treat at least 3 millioninfected people by the end of 2005.
Dr. Wainberg is a professor of virology and the director of the AIDS Centre at the Jewish General Hospital, McGill University, Montreal.
This article has been cited by other articles:
Chokshi, D. A., Rajkumar, R.
(2007). Leveraging University Research to Advance Global Health. JAMA
298: 1934-1936
[Full Text]
Bartlett, J. A., Muro, E. P.
(2007). Generic and Branded Drugs for the Treatment of People Living With HIV/AIDS. J Int Assoc Physicians AIDS Care (Chic Ill)
6: 15-23
[Abstract]
Manasa, J., Musabaike, H., Masimirembwa, C., Burke, E., Luthy, R., Mudzori, J.
(2007). Evaluation of the Partec Flow Cytometer against the BD FACSCalibur System for Monitoring Immune Responses of Human Immunodeficiency Virus-Infected Patients in Zimbabwe. CVI
14: 293-298
[Abstract][Full Text]
Nuesch, R., Srasuebkul, P., Ananworanich, J., Ruxrungtham, K., Phanuphak, P., Duncombe, C., on behalf of the HIV-NAT Study Team,
(2006). Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. J Antimicrob Chemother
58: 637-644
[Abstract][Full Text]
